10x Genomics announced the launch of Atera on April 18, 2026, unveiling the platform at the AACR Annual Meeting that ran from April 17 to 22. Atera is a new in‑situ spatial biology system that delivers whole‑transcriptome analysis with single‑cell sensitivity and sub‑cellular resolution without the need for conventional sequencing.
The platform is engineered to process up to 800 whole‑transcriptome samples of 1 cm² per year, a projected capability that far exceeds the throughput of existing 10x Genomics spatial platforms such as Xenium and Visium. Atera’s chemistry, hardware, and software are optimized to enable whole‑transcriptome profiling at single‑cell resolution across both fresh‑frozen and FFPE tissue, addressing a key limitation of current spatial technologies.
The spatial biology market is projected to exceed $1 billion by 2030, and Atera positions 10x Genomics to capture a larger share of this growth. The platform competes directly with Visium HD, which offers whole‑transcriptome coverage, and Xenium, which provides targeted high‑plex imaging. By combining whole‑transcriptome coverage with single‑cell sensitivity and sub‑cellular resolution, Atera offers a unique value proposition that could give 10x a competitive edge over rivals such as Akoya Biosciences and Vizgen.
Financially, 10x Genomics reported Q4 2025 revenue of $166.0 million, a 1% year‑over‑year increase, and full‑year 2025 revenue of $642.8 million, a 2% decline when excluding non‑recurring patent litigation revenue. The company’s full‑year 2026 guidance is $600 million to $625 million, representing 0% to 4% growth over 2025. These figures illustrate the company’s steady revenue base while it invests in new platforms like Atera.
CEO Serge Saxonov said, "At 10x, our mission is to accelerate the mastery of biology to advance human health." He added, "Atera marks a fundamental shift in how biology is analyzed and understood." Saxonov also noted, "We rethought the system from the ground up, optimizing each component across chemistry, hardware and software to enable what was previously impossible in spatial analysis."
Pre‑orders for Atera are currently open, with shipping expected in the second half of 2026. The launch expands 10x Genomics’ portfolio beyond consumables and reinforces its leadership in the single‑cell and spatial biology infrastructure space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.